Lakefront Biotherapeutics (GLPGF) Short-term Investments (2014 - 2023)

Lakefront Biotherapeutics (GLPGF) has reported Short-term Investments for 10 consecutive years, with $102.2 million the latest figure, recorded in Q4 2023.

• On a quarterly basis, Short-term Investments rose 100.37% year-over-year to $102.2 million in Q4 2023; TTM through Dec 2023 was $102.2 million, a 100.37% increase from a year earlier, with the FY2023 full-year figure at $102.2 million, up 100.37% from the prior year.
• Short-term Investments was $102.2 million for Q4 2023 at Lakefront Biotherapeutics, up from $51.0 million in the prior quarter.
• Over five years, Short-term Investments peaked at $1.7 billion in Q2 2021 and troughed at $51.0 million in Q4 2022.
• A 5-year average of $874.4 million and a median of $1.1 billion in 2019 frame the typical range for Short-term Investments.
• Across the five-year window, Short-term Investments jumped 122.69% in 2020 and sank 95.57% in 2022, its largest moves.
• Over 5 years, Short-term Investments stood at $1.1 billion in 2019, then grew by 1.11% to $1.1 billion in 2020, then increased by 7.99% to $1.2 billion in 2021, then slumped by 95.57% to $51.0 million in 2022, then soared by 100.37% to $102.2 million in 2023.
• The last three Short-term Investments figures came in at $102.2 million (Q4 2023), $51.0 million (Q4 2022), and $1.2 billion (Q4 2021), per Business Quant data.